Education
PhD - Baylor College of Medicine, Houston, TX
BS - Vilnius University, Vilnius, Lithuania
Research Interests
Major research focus - developing an effective immunotherapy for gliomas using genetically modified T cells.
Current projects goals are:
- Generating and optimizing CAR T-cells to target glioma associated antigens
- Enhancing CAR T cell effector functions by different genetic manipulations to render them resistant to tumor microenvironment
- Understanding tumor escape mechanism in order to design superior immunotherapy based treatments.
Selected Publications
Prinzing BL, Gottschalk SM, Krenciute G. CAR T-cell therapy for glioblastoma: ready for the next round of clinical testing? Expert review of anticancer therapy 1-11, 2018. PMID: 29533108
Pituch KC, Miska J, Krenciute G, Panek WK, Li G, Rodriguez-Cruz T, Wu M, Han Y, Lesniak MS, Gottschalk S, Balyasnikova IV. Adoptive Transfer of IL13Rα2-Specific Chimeric Antigen Receptor T Cells Creates a Pro-inflammatory Environment in Glioblastoma. Molecular therapy: the journal of the American Society of Gene Therapy 2018. PMID: 29503195
Yi Z, Brooke LP, Cao F, Gottschalk S, Krenciute G. Optimizing EphA2-CAR T cells for the Adoptive Immunotherapy of Glioma. Molecular Therapy - Methods & Clinical Development February 15; 9:70-80, 2018.
Mamonkin M, Mukherjee M, Srinivasan M, Sharma S, Gomes-Silva D, Mo F, Krenciute G, Orange JS, Brenner MK. Reversible Transgene Expression Reduces Fratricide and Permits 4-1BB Costimulation of CAR T Cells Directed to T-Cell Malignancies. Cancer Immunol Res Oct 27, 2017. pii: canimm.0126.2017. doi: 10.1158/2326-6066.CIR-17-0126. PMID: 29079655
Gomes-Silva D, Mukherjee M, Srinivasan M, Krenciute G, Dakhova O, Zheng Y, Cabral JMS, Rooney CM, Orange JS, Brenner MK, Mamonkin M. Tonic 4-1BB Costimulation in Chimeric Antigen Receptors Impedes T Cell Survival and Is Vector-Dependent. Cell Rep Oct 3;21(1):17-26, 2017. doi: 10.1016/j.celrep.2017.09.015. PMID: 28978471
Mata M, Gerken C, Nguyen P, Krenciute G, Spencer DM, Gottschalk S. Inducible activation of MyD88 and CD40 in CAR T-cells results in controllable and potent antitumor activity in preclinical solid tumor models. Cancer Discov Aug 11, 2017. pii: CD-17-0263. doi: 10.1158/2159-8290.CD-17-0263. PMID: 28801306
Krenciute G, Prinzing BL, Yi Z, Wu MF, Liu H, Dotti G, Balyasnikova IV, Gottschalk S. Transgenic expression of IL15 improves antiglioma activity of IL13Ralpha2-CAR T cells but results in antigen-loss variants. Cancer Immunol Res Jul;5(7):571-581, 2017. PMID: 28550091.
Krenciute G, Krebs S, Torres D, Wu MF, Liu H, Dotti G, Li XN, Lesniak MS, Balyasnikova IV, Gottschalk S. Characterization and functional analysis of scFv-based CARs to redirect T cells to IL13Rα2-positive glioma. Mol Ther Feb;24(2):354-63, 2016 PMID: 26514825. doi: 10.1038/mt.2015.199.
Krenciute G, Liu S, Yi S, Yucer N, Ortiz P, Liu Q, Kim BJ, Odejimi OA, Leng M, Qin J, Wang Y. Nuclear BAG6-UBL4A-GET4 complex mediates DNA damage signaling and cell death. J Biol Chem Jul 12;288(28):20547-57, 2013. PMID: 23723067
Malovannaya A, Lanz RB, Jung SY, Bulynko Y, Le NT, Chan DW, Ding C, Shi Y, Yucer N, Krenciute G, Kim BJ, Li C, Chen R, Li W, Wang Y, O'Malley BW, Qin J. Analysis of the human endogenous coregulator complexome. Cell May 27;145(5):787-99, 2011. PMID: 21620140
Last update: March 2018